Edgewise Therapeutics annual return on equity
2021
2022
2023
2024
2025
Edgewise Therapeutics Return on Equity (ROE) Growth & History (EWTX)
Edgewise Therapeutics's return on equity was −34.19% for fiscal 2025.
View full Edgewise Therapeutics company overviewEdgewise Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −34.19% | +0.20 pp |
| 2024 | 2024-12-31 | −34.40% | −4.30 pp |
| 2023 | 2023-12-31 | −30.10% | −8.32 pp |
| 2022 | 2022-12-31 | −21.78% | +13.75 pp |
| 2021 | 2021-12-31 | −35.53% | — |
Edgewise Therapeutics quarterly return on equity
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −12.18% | −5.09 pp |
| Q1 2026 | 2026-03-31 | −9.65% | −0.47 pp |
| Q4 2025 | 2025-12-31 | −9.29% | −0.92 pp |
| Q3 2025 | 2025-09-30 | −7.09% | −0.26 pp |
| Q2 2025 | 2025-06-30 | −7.09% | −1.06 pp |
| Q1 2025 | 2025-03-31 | −9.18% | −2.50 pp |
| Q4 2024 | 2024-12-31 | −8.37% | +1.53 pp |
| Q3 2024 | 2024-09-30 | −6.83% | +1.71 pp |
| Q2 2024 | 2024-06-30 | −6.03% | +0.68 pp |
| Q1 2024 | 2024-03-31 | −6.68% | +0.08 pp |
| Q4 2023 | 2023-12-31 | −9.90% | −4.41 pp |
| Q3 2023 | 2023-09-30 | −8.54% | −2.79 pp |
| Q2 2023 | 2023-06-30 | −6.71% | −0.36 pp |
| Q1 2023 | 2023-03-31 | −6.76% | −1.28 pp |
| Q4 2022 | 2022-12-31 | −5.48% | −0.95 pp |
| Q3 2022 | 2022-09-30 | −5.76% | −1.31 pp |
| Q2 2022 | 2022-06-30 | −6.34% | −2.91 pp |
| Q1 2022 | 2022-03-31 | −5.48% | −0.49 pp |
| Q4 2021 | 2021-12-31 | −4.54% | — |
| Q3 2021 | 2021-09-30 | −4.45% | — |
| Q2 2021 | 2021-06-30 | −3.43% | — |
| Q1 2021 | 2021-03-31 | −4.99% | — |
Edgewise Therapeutics return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Edgewise Therapeutics's return on equity increased from −35.53% to −34.19%, a change of +1.34 percentage points. The latest reported quarter, Q2 2026, shows −12.18%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Edgewise Therapeutics source filings ↗